Diabetes IN hospital - Glucose and Outcomes in the COVID-19 pandemic (DINGO COVID-19): the 2020 Melbourne hospital experience prior to novel variants and vaccinations.
Rahul D BarmanrayJoanna Y GongMervyn KyiDev KevatMohammad A IslamAnna GalliganGeorgina R ManosIndu V NairNayomi PereraNicholas K AdamsAshvin NursingAnnabelle M WarrenPeter Shane HamblinRichard J MacIsaacElif Ilhan EkinciBalasubramanian KrishnamurthyHarin KarunajeewaKirsty BuisingKumar VisvanathanThomas W H KaySpiros FourlanosPublished in: Internal medicine journal (2022)
During the first year of the COVID-19 pandemic, in-hospital hyperglycaemia and known diabetes were not associated with in-hospital mortality, contrasting with published international experiences. This likely mainly relates to hyperglycaemia indicating receipt of mortality-reducing dexamethasone therapy. These differences in published experiences underscore the importance of understanding population and clinical treatment factors affecting glycaemia and COVID-19 morbidity within both local and global contexts.
Keyphrases
- coronavirus disease
- sars cov
- type diabetes
- healthcare
- cardiovascular disease
- acute care
- glycemic control
- mental health
- adverse drug
- low dose
- stem cells
- randomized controlled trial
- blood glucose
- cardiovascular events
- gene expression
- emergency department
- copy number
- metabolic syndrome
- insulin resistance
- cell therapy
- skeletal muscle